Tozasertib has entered phase I/II clinical trials for the treatment of solid tumours44, chronic myeloid leukaemia and acute lymphocytic leukaemia with T351I BCR-ABL mutations45–47. Here, ABL1 is linked to acute lymphoblastic leukemia.